Product Description
Mechanisms of Action: 4-1BB Inhibitor,GPC3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BeiGene
Company Location: GRAND CAYMAN E9 KY1-1108
Company CEO: John V. Oyler
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for BGB-B2033](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Endodermal Sinus Tumor|Gastrointestinal Cancer|Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BGB-B2033-101 | P1 |
Not yet recruiting |
Endodermal Sinus Tumor|Squamous Cell Carcinoma|Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer |
2026-10-30 |